(Q33774675)

29 July 2017

Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge (English)

1 reference

29 July 2017

0 references

John A Eckman

1

1 reference

29 July 2017

Patricia M Sterba

2

1 reference

29 July 2017

Denise Kelly

3

1 reference

29 July 2017

Val Alexander

4

1 reference

29 July 2017

Mark C Liu

5

1 reference

29 July 2017

Bruce S Bochner

6

1 reference

29 July 2017

Donald W Macglashan

7

1 reference

29 July 2017

Sarbjit S Saini

8

1 reference

29 July 2017

language of work or name

English

0 references

publication date

4 December 2009

1 reference

The Journal of Allergy and Clinical Immunology

29 July 2017

1 reference

29 July 2017

125

1 reference

29 July 2017

4

1 reference

29 July 2017

889-895.e7

1 reference

Newly discovered roles for basophils: a neglected minority gains new respect.

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

28 July 2018

Omalizumab for asthma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Omalizumab inhibits allergen challenge-induced nasal response

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Humanization of an antibody directed against IgE

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Basophil histamine release decreases during omalizumab therapy in allergic asthmatics.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Basophil FcepsilonRI histamine release parallels expression of Src-homology 2-containing inositol phosphatases in chronic idiopathic urticaria.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Objective monitoring of nasal patency and nasal physiology in rhinitis

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Expression and modulation of FcepsilonRIalpha and FcepsilonRIbeta in human blood basophils

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2850969

Therapeutic efficacy of omalizumab

30 October 2018

1 reference

12 December 2020

Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay

1 reference

12 December 2020

Inflammatory mediators in late antigen-induced rhinitis

1 reference

12 December 2020

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo

1 reference

12 December 2020

Symptom scores as measures of the severity of rhinitis

1 reference

12 December 2020

Tryptase and histamine as markers to evaluate mast cell activation during the responses to nasal challenge with allergen, cold, dry air, and hyperosmolar solutions

1 reference

12 December 2020

10.1016/J.JACI.2009.09.012

Identifiers

DOI

1 reference

release_lx4dqrnz65glxgchcbkp74ftyq

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lx4dqrnz65glxgchcbkp74ftyq

24 November 2022

mapped directly with Wikidata item

PMCID

2850969

1 reference

29 July 2017

1 reference